dose conversion tirzepatide to semaglutide Switching from Switching from Semaglutide to Tirzepatide:

Retatrutide Phase 3 TRIUMPH-4 (NCT05931367, 445 participants, 68 weeks) reported 28.7% body weight loss at 12 mg, 26.4% at 9 mg, vs 2.1% placebo

Advanced LC-HRMS methods are often required to improve sensitivity and resolution while evaluating important critical quality attributes (CQAs) in biosimilars

encourages healthcare providers to prescribe glucagon-like peptide 1 (GLP-1) analogues

Direct Meds Company Background According to publicly available business records, Direct Meds, LLC was incorporated in May 2024

In cardiovascular outcome trials of semaglutide in type 2 diabetes, rapid improvements in glycemic control were associated with an increased rate of diabetic retinopathy complications in high-risk patients, likely reflecting the well-known phenomenon of transient retinopathy worsening when glucose control improves quickly.9 More recently, observational analyses and pharmacovigilance reports have raised a possible association between semaglutide exposure and nonarteritic anterior ischemic optic neuropathy (NAION), leading to ongoing regulatory review